

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Geoffrey Brooke
Date of last notice	7 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect 3. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary 3. Dalhigh Pty Ltd <Dalhigh Investments A/C> - Director and beneficiary
Date of change	4 November 2024
No. of securities held prior to change	1. 14,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 1,554,039 fully paid ordinary shares 5,000,000 unlisted options ex @ \$0.10 exp 24/3/2025 275,331 unlisted options ex @ \$0.0375 exp 11/9/2026 501,689 unlisted options ex @ \$0.05 exp 31/5/2027 2. 2,801,365 fully paid ordinary shares. 237,029 unlisted options ex @ \$0.0375 exp 11/9/2026 87,543 unlisted options ex @ \$0.05 exp 31/5/2027
Class	Fully paid ordinary shares Listed options ex @ \$0.05 exp 30/9/2027
Number acquired	3. 1,666,668 fully paid ordinary shares 1,250,001 listed options ex @ \$0.05 exp 30/9/2027
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$50,000.04
No. of securities held after change	<ol style="list-style-type: none"> 14,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 1,554,039 fully paid ordinary shares 5,000,000 unlisted options ex @ \$0.10 exp 24/3/2025 275,331 unlisted options ex @ \$0.0375 exp 11/9/2026 501,689 unlisted options ex @ \$0.05 exp 31/5/2027 2,801,365 fully paid ordinary shares. 237,029 unlisted options ex @ \$0.0375 exp 11/9/2026 87,543 unlisted options ex @ \$0.05 exp 31/5/2027 1,666,668 fully paid ordinary shares 1,250,001 listed options ex @ \$0.05 exp 30/9/2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director placement shares and free attaching listed options following shareholder approval on 4 November 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Steven Gourlay
Date of last notice	7 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. SG Gourlay Nominees Pty Ltd <SF Gourlay Family A/C> - Director of trustee and beneficiary of trust
Date of change	4 November 2024
No. of securities held prior to change	1. 68,362,300 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 7,670,607 fully paid ordinary shares. 702,864 unlisted options ex @ \$0.0375 exp 11/9/2026 1,757,440 unlisted options ex @ \$0.05 exp 31/5/2027 2. 20,561,907 fully paid ordinary shares. 1,739,783 unlisted options ex @ \$0.0375 exp 11/9/2026 642,560 unlisted options ex @ \$0.05 exp 31/5/2027
Class	Fully paid ordinary shares Listed options ex @ \$0.05 exp 30/9/2027
Number acquired	1. 33,333,334 fully paid ordinary shares 25,000,000 unlisted options ex @ \$0.05 exp 31/5/2027
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$1,000,000.02
No. of securities held after change	<ol style="list-style-type: none"> 68,362,300 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 41,003,941 fully paid ordinary shares. 702,864 unlisted options ex @ \$0.0375 exp 11/9/2026 1,757,440 unlisted options ex @ \$0.05 exp 31/5/2027 25,000,000 listed options ex \$0.05 exp 30/9/2027 20,561,907 fully paid ordinary shares. 1,739,783 unlisted options ex @ \$0.0375 exp 11/9/2026 642,560 unlisted options ex @ \$0.05 exp 31/5/2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director placement shares and free attaching listed options following shareholder approval on 4 November 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr George Morstyn
Date of last notice	7 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary
Date of change	4 November 2024
No. of securities held prior to change	1. 2,843,289 fully paid ordinary shares 5,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 299,805 unlisted options ex @ \$0.0375 exp 11/9/2026 260,728 unlisted options ex @ \$0.05 exp 31/5/2027 2. 3,631,506 fully paid ordinary shares. 307,269 unlisted options ex @ \$0.0375 exp 11/9/2026. 113,485 unlisted options ex @ \$0.05 exp 31/5/2027
Class	Fully paid ordinary shares Listed options ex @ \$0.05 exp 30/9/2027
Number acquired	2. 1,666,668 fully paid ordinary shares 1,250,001 listed options ex @ \$0.05 exp 30/9/2027
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$50,000.04
No. of securities held after change	<ol style="list-style-type: none"> 2,843,289 fully paid ordinary shares 5,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 299,805 unlisted options ex @ \$0.0375 exp 11/9/2026 260,728 unlisted options ex @ \$0.05 exp 31/5/2027 5,300,174 fully paid ordinary shares. 307,269 unlisted options ex @ \$0.0375 exp 11/9/2026. 113,485 unlisted options ex @ \$0.05 exp 31/5/2027 1,250,001 listed options ex \$0.05 exp 30/9/2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director placement shares and free attaching listed options following shareholder approval on 4 November 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Malcolm McComas
Date of last notice	7 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect 3. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. Bunyula Super Pty Ltd <Bunyula Super Fund A/C> - director related entity and contingent beneficial interest 3. McComas Capital Pty Ltd <McComas Family A/C> - controller of trustee & a beneficiary of the trust 4. Speech Dynamics Pty Ltd – director related entity
Date of change	4 November 2024
No. of securities held prior to change	1. 4,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan 300,000 fully paid ordinary shares 150,000 unlisted options ex @ \$0.05 exp 31/5/2027 2. 1,070,219 fully paid ordinary shares 90,554 unlisted options ex @ \$0.0375 exp 11/9/2026 33,445 unlisted options ex @ \$0.05 exp 31/5/2027 3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan 301,617 fully paid ordinary shares 110,133 unlisted options ex @ \$0.0375 exp 11/9/2026 40,676 unlisted options ex @ \$0.05 exp 31/5/2027
Class	Fully paid ordinary shares Listed options ex @ \$0.05 exp 30/9/2027
Number acquired	4. 1,000,000 fully paid ordinary shares 750,000 listed options ex @ \$0.05 exp 30/9/2027
Number disposed	-
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$30,000.00

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 1. 4,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan 300,000 fully paid ordinary shares 150,000 unlisted options ex @ \$0.05 exp 31/5/2027 2. 1,070,219 fully paid ordinary shares 90,554 unlisted options ex @ \$0.0375 exp 11/9/2026 33,445 unlisted options ex @ \$0.05 exp 31/5/2027 3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan 301,617 fully paid ordinary shares 110,133 unlisted options ex @ \$0.0375 exp 11/9/2026 40,676 unlisted options ex @ \$0.05 exp 31/5/2027 4. 1,000,000 fully paid ordinary shares 750,000 listed options ex \$0.05 exp 30/9/2027
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Director placement shares and free attaching listed options following shareholder approval on 4 November 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.